Role of Bile Acids and Gut Bacteria in GI Diseases
Role of Bile Acids and Gut Bacteria in GI Diseases
批准号:
8698288
负责人:
PHILLIP B HYLEMON
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-01 至 2016-06-30
关键词:
AcidsActive SitesAmino AcidsAndrogensApplications GrantsBacteriaBile AcidsBile fluidBindingBiochemical PathwayBiological AssayBloodChemicalsChenodeoxycholic AcidCholelithiasisCholesterolCholic AcidsClinical ResearchClostridiumColonColon CarcinomaDNADataDeoxycholic AcidDetectionDevelopmentDietDiseaseEcosystemEnterohepatic CirculationEnzyme KineticsEnzymesFecesFutureGene Expression ProfileGenesGlucocorticoidsGoalsGrowthHealthHospitalsHumanHuman MicrobiomeHydro-LyasesIncidenceIndividualIntestinesLaboratoriesLithocholic AcidLiverMammalian CellMetabolic BiotransformationMetabolismMolecularMonitorOxidoreductasePathway interactionsPatientsPhysiologicalPlayPopulationProstateProteinsRNAReverse Transcriptase Polymerase Chain ReactionRiskRoleSamplingSecondary toSite-Directed MutagenesisSteroid 17-alpha-monooxygenaseSteroidsSterolsSubstrate SpecificityTechniquesTimeTissuesVirginiaarmdehydroxylationdisorder riskin vivoinhibitor/antagonistmenmillimetermutantnovelpatient populationsteroid hormonethree dimensional structuretooltranscriptome sequencingtumor growth
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
The human colon harbors one of the most densely populated bacterial ecosystems known (>1011 bacteria/g feces). Cholic acid (CA) and chenodeoxycholic acid (CDCA) are primary bile acids synthesized from cholesterol in the liver. Bile acids undergo enterohepatic circulation several times each day. Primary bile acids entering the colon are deconjugated and free bile acids are biotransformed to more than 20 different metabolites by gut bacteria. The major biotransformation is 7¿-dehydroxylation (7¿- DeOH) of CA and CDCA yielding the secondary bile acids deoxycholic acid (DCA) and lithocholic acid (LCA), respectively. Hydrophobic secondary bile acids are highly toxic to mammalian cells and can accumulate to high levels (>70%) in the bile acid pool of some individuals as the human liver cannot 7¿-hydroxylate secondary bile acids. High levels of DCA in blood, bile, and feces have been correlated with an increase risk of colon cancer and cholesterol gallstone disease, in some patients. The formation of secondary bile acids is carried out by a few species of the genus Clostridium and the level of these bacteria in feces is correlated with DCA levels in bile. The biochemical pathway of bile acid 7¿-DeOH has been elucidated by our group. However, many of the genes encoding enzymes in this pathway have not been isolated and characterized nor have the 3D structure of key enzymes in this pathway determined. Some strains of 7¿- dehydroxylating bacteria can convert glucocorticoids into C-19 androgenic compounds and the genes encoding these enzymes have not been isolated. Isolation of these genes is crucial for the development of molecular techniques (RT-PCR) to easily monitor intestinal bile acid and glucocorticoid metabolism and pharmacological or dietary ways to decrease formation of secondary bile acids and C-19 androgenic compounds. Subaim 1A. Identify CA, allo-CA, and glucocorticoid inducible genes from the human bile acid 7¿-dehydroxylating bacterium, Clostridium scindens ATCC 35704, via a wholetranscriptome approach (RNAseq). Subaim 1B. Develop quantitative PCR assays for key genes involved in allo-DCA and C-19 androgen formation. Aim 2. Characterize the allo-CA and glucocorticoid inducible enzymes from Clostridium scindens ATCC 35704 catalyzing the formation of allo-DCA acid and C-19 androgens, respectively. Aim 3: Determine the 3D structure of bile acid 7¿ and 7¿-dehydratases, the rate limiting enzymes in bile acid 7¿/7¿-DeOH, from Clostridium scindens. The results of these studies will give us the tools to carry out clinical studies to determine the most effective ways to decrease DCA in the bile acid pool with the aim of decreasing the risk of colon cancer and cholesterol gallstones, in some patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Sphingolipids in alcoholic liver disease
-
批准号:10608594
-
项目类别:
-
资助金额:$52.31万
-
财政年份:2023
-
负责人:PHILLIP B HYLEMON
-
依托单位:
LncRNA H19 in Cholestatic Liver Diseases
-
批准号:10202570
-
项目类别:
-
资助金额:$53.65万
-
财政年份:2018
-
负责人:PHILLIP B HYLEMON
-
依托单位:
LncRNA H19 in Cholestatic Liver Diseases
-
批准号:10909545
-
项目类别:
-
资助金额:$62.96万
-
财政年份:2018
-
负责人:PHILLIP B HYLEMON
-
依托单位:
LncRNA H19 in Cholestatic Liver Diseases
-
批准号:9750721
-
项目类别:
-
资助金额:$53.65万
-
财政年份:2018
-
负责人:PHILLIP B HYLEMON
-
依托单位:
Bile Acid and Sphingosine-1-phosphate Receptor-mediated Signaling in Cholestasis
-
批准号:9024718
-
项目类别:
-
资助金额:$41.17万
-
财政年份:2015
-
负责人:PHILLIP B HYLEMON
-
依托单位:
Bile Acids and Clostridium scindens Inhibit C. difficile: Role of Secreted Antibacterial Compounds
-
批准号:9233344
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:PHILLIP B HYLEMON
-
依托单位:
Role of Bile Acids and Gut Bacteria in GI Diseases
-
批准号:8536579
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:PHILLIP B HYLEMON
-
依托单位:
Role of Bile Acids and Gut Bacteria in GI Diseases
-
批准号:8324091
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:PHILLIP B HYLEMON
-
依托单位:
HIV Protease Inhibitors and Hepatic Lipid Dysregulation
-
批准号:7035831
-
项目类别:
-
资助金额:$32.44万
-
财政年份:2004
-
负责人:PHILLIP B HYLEMON
-
依托单位:
HIV Protease Inhibitors and Hepatic Lipid Dysregulation
-
批准号:6799002
-
项目类别:
-
资助金额:$33.25万
-
财政年份:2004
-
负责人:PHILLIP B HYLEMON
-
依托单位:
HIV Protease Inhibitors and Hepatic Lipid Dysregulation
-
批准号:6861103
-
项目类别:
-
资助金额:$33.23万
-
财政年份:2004
-
负责人:PHILLIP B HYLEMON
-
依托单位:
HIV Protease Inhibitors and Hepatic Lipid Dysregulation
-
批准号:7189897
-
项目类别:
-
资助金额:$31.48万
-
财政年份:2004
-
负责人:PHILLIP B HYLEMON
-
依托单位:
HIV Protease Inhibitors and Hepatic Lipid Dysregulation
-
批准号:7371133
-
项目类别:
-
资助金额:$30.87万
-
财政年份:2004
-
负责人:PHILLIP B HYLEMON
-
依托单位:
BILE ACID SIGNALING & HEPATIC CHOLESTEROL METABOLISM
-
批准号:6369833
-
项目类别:
-
资助金额:$26.1万
-
财政年份:2001
-
负责人:PHILLIP B HYLEMON
-
依托单位:
BILE ACID SIGNALING & HEPATIC CHOLESTEROL METABOLISM
-
批准号:6524254
-
项目类别:
-
资助金额:$26.1万
-
财政年份:2001
-
负责人:PHILLIP B HYLEMON
-
依托单位:
Regulation of Hepatic SphK2 by Bile Acids: Effects on Lipid Metabolism
-
批准号:8824513
-
项目类别:
-
资助金额:$32.52万
-
财政年份:2001
-
负责人:PHILLIP B HYLEMON
-
依托单位:
BILE ACID SIGNALING & HEPATIC CHOLESTEROL METABOLISM
-
批准号:6787328
-
项目类别:
-
资助金额:$26.1万
-
财政年份:2001
-
负责人:PHILLIP B HYLEMON
-
依托单位:
Bile Acid Activated Cell Signaling in the Liver and Nutrition
-
批准号:7629638
-
项目类别:
-
资助金额:$28.64万
-
财政年份:2001
-
负责人:PHILLIP B HYLEMON
-
依托单位:
BILE ACID SIGNALING & HEPATIC CHOLESTEROL METABOLISM
-
批准号:6661859
-
项目类别:
-
资助金额:$26.1万
-
财政年份:2001
-
负责人:PHILLIP B HYLEMON
-
依托单位:
BILE ACID SIGNALING & HEPATIC CHOLESTEROL METABOLISM
-
批准号:6931638
-
项目类别:
-
资助金额:$26.1万
-
财政年份:2001
-
负责人:PHILLIP B HYLEMON
-
依托单位:
海外基金